{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:59:55Z","timestamp":1762642795515,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Italian  Minister of Health","award":["Ricerca Corrente program 2022-2024"],"award-info":[{"award-number":["Ricerca Corrente program 2022-2024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Germline mutations in cancer susceptibility genes were identified in pancreatic cancer (PanC) patients with a sporadic disease and in those unselected for family cancer history.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>With the aim to determine the prevalence of germline predisposition genes mutations in PanC, and to evaluate whether they were associated with the presence of PanC, we profiled a custom AmpliSeq panel of 27 cancer susceptibility genes in 47 PanC patients and 51 control subjects by using the Ion Torrent PGM system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Multigene panel testing identified a total of 31 variants in 27 PanC (57.4%), including variants with pathogenic\/likely pathogenic effect, those of uncertain significance, and variants whose clinical significance remains currently undefined. Five patients carried more than one variant in the same gene or in different genes. Eight patients (17.0%) had at least one pathogenic\/likely pathogenic variant in four main genes: CFTR (10.6%), BRCA2 (8.5%), ATM and CHEK2 (2.1%). Pathogenic\/likely pathogenic mutation were identified in patients with positive PanC family history (20%) or in patients without first-degree relatives affected by PanC (13.6%). All the BRCA2 mutation carriers were unselected PanC patients. The presence of mutations in BRCA2 was significantly associated with an increased occurrence of PanC and with positive family history for endometrial cancer (p\u2009=\u20090.018).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study confirmed the potential remarkable contribution of BRCA2 in assessing the presence of PanC. Overall our findings supported the recommendation of offering the germline testing to all the PanC patients with the intent to reduce the number of underdiagnosed carriers of mutations in predisposition genes, and not to preclude their relatives from the opportunity to benefit from surveillance programs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10020-023-00600-1","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T10:04:04Z","timestamp":1675073044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study"],"prefix":"10.1186","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8831-7349","authenticated-orcid":false,"given":"Francesca","family":"Tavano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenica","family":"Gioffreda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orazio","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Latiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Latiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana Pia","family":"Latiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Scaramuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evaristo","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Bazzocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"issue":"4","key":"600_CR1","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s11605-011-1781-6","volume":"16","author":"W Al-Sukhni","year":"2012","unstructured":"Al-Sukhni W, Borgida A, Rothenmund H, Holter S, Semotiuk K, Grant R, et al. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg. 2012;16(4):771\u201383. https:\/\/doi.org\/10.1007\/s11605-011-1781-6.","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"600_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.suc.2008.04.012","volume":"88","author":"W Al-Sukhni","year":"2008","unstructured":"Al-Sukhni W, Aronson M, Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. Surg Clin North Am. 2008;88(4):819\u201344. https:\/\/doi.org\/10.1016\/j.suc.2008.04.012.","journal-title":"Surg Clin North Am"},{"key":"600_CR3","unstructured":"American Cancer Society. Key statistics for pancreatic cancer. [American Cancer Sociaty About pancreatic Cancer website]. http:\/\/www.cancer.org\/cancer\/pancreatic-cancer\/about\/key-statistics.html. Accessed 4 Sep 2018."},{"issue":"8","key":"600_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00535-021-01806-y","volume":"56","author":"E Astiazaran-Symonds","year":"2021","unstructured":"Astiazaran-Symonds E, Goldstein AM. A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer. J Gastroenterol. 2021;56(8):713\u201321. https:\/\/doi.org\/10.1007\/s00535-021-01806-y.","journal-title":"J Gastroenterol"},{"key":"600_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.dnarep.2017.06.003","volume":"56","author":"SR Barbari","year":"2017","unstructured":"Barbari SR, Shcherbakova PV. Replicative DNA polymerase defects in human cancers: consequences, mechanisms, and implications for therapy. DNA Repair. 2017;56:16\u201325. https:\/\/doi.org\/10.1016\/j.dnarep.2017.06.003.","journal-title":"DNA Repair"},{"issue":"3","key":"600_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/AOG.0b013e3181ec5fc1","volume":"116","author":"JS Berek","year":"2010","unstructured":"Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol. 2010;116(3):733\u201343. https:\/\/doi.org\/10.1097\/AOG.0b013e3181ec5fc1.","journal-title":"Obstet Gynecol"},{"issue":"8","key":"600_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/gim.2017.185","volume":"20","author":"DD Buchanan","year":"2018","unstructured":"Buchanan DD, Stewart JR, Clendenning M, Rosty C, Mahmood K, Pope BJ, et al. Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1. Genet Med. 2018;20(8):890\u20135. https:\/\/doi.org\/10.1038\/gim.2017.185.","journal-title":"Genet Med"},{"issue":"3","key":"600_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/gutjnl-2012-303108","volume":"62","author":"MI Canto","year":"2013","unstructured":"Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339\u201347. https:\/\/doi.org\/10.1136\/gutjnl-2012-303108. Hammell, Pascal [corrected to Hammel, Pascal]. Erratum in: Gut. 2014;63(1):178.","journal-title":"Gut"},{"issue":"9","key":"600_CR9","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1097\/MPA.0000000000001145","volume":"47","author":"IM Cazacu","year":"2018","unstructured":"Cazacu IM, Farkas N, Garami A, Balask\u00f3 M, Mosd\u00f3si B, Alizadeh H, et al. Pancreatitis-associated genes and pancreatic cancer risk: a systematic review and meta-analysis. Pancreas. 2018;47(9):1078\u201386. https:\/\/doi.org\/10.1097\/MPA.0000000000001145.","journal-title":"Pancreas"},{"issue":"2","key":"600_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/0008-5472.383.65.2","volume":"65","author":"FJ Couch","year":"2005","unstructured":"Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, de Andrade M, et al. Germline Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res. 2005;65(2):383\u20136.","journal-title":"Cancer Res"},{"issue":"2","key":"600_CR11","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/1055-9965","volume":"16","author":"FJ Couch","year":"2007","unstructured":"Couch FJ, Johnson MR, Rabe KG, Brune K, de Andrade M, Goggins M, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(2):342\u20136. https:\/\/doi.org\/10.1158\/1055-9965.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"600_CR12","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1002\/cam4.2973","volume":"9","author":"C Cremin","year":"2020","unstructured":"Cremin C, Lee MK, Hong Q, Hoeschen C, Mackenzie A, Dixon K, et al. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Cancer Med. 2020;9(11):4004\u201313. https:\/\/doi.org\/10.1002\/cam4.2973.","journal-title":"Cancer Med"},{"issue":"6","key":"600_CR13","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1086\/426403","volume":"75","author":"C Cybulski","year":"2004","unstructured":"Cybulski C, G\u00f3rski B, Huzarski T, Masoj\u0107 B, Mierzejewski M, Debniak T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75(6):1131\u20135. https:\/\/doi.org\/10.1086\/426403.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"600_CR14","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1053\/gast.2002.37042","volume":"123","author":"C Durno","year":"2002","unstructured":"Durno C, Corey M, Zielenski J, Tullis E, Tsui LC, Durie P. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology. 2002;123(6):1857\u201364. https:\/\/doi.org\/10.1053\/gast.2002.37042.","journal-title":"Gastroenterology"},{"issue":"4","key":"600_CR15","first-page":"1417","volume":"31","author":"DR Fogelman","year":"2011","unstructured":"Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, et al. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res. 2011;31(4):1417\u201320.","journal-title":"Anticancer Res"},{"issue":"1","key":"600_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/gutjnl-2019-319352","volume":"69","author":"M Goggins","year":"2020","unstructured":"Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7\u201317. https:\/\/doi.org\/10.1136\/gutjnl-2019-319352. Erratum. In: Gut. 2020;69(6):e3.","journal-title":"Gut"},{"issue":"3","key":"600_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1053\/j.gastro.2014.11.042","volume":"148","author":"RC Grant","year":"2015","unstructured":"Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015;148(3):556\u201364. https:\/\/doi.org\/10.1053\/j.gastro.2014.11.042.","journal-title":"Gastroenterology"},{"issue":"21","key":"600_CR18","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","volume":"93","author":"LC Hartmann","year":"2001","unstructured":"Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633\u20137. https:\/\/doi.org\/10.1093\/jnci\/93.21.1633.","journal-title":"J Natl Cancer Inst"},{"issue":"28","key":"600_CR19","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","volume":"33","author":"S Holter","year":"2015","unstructured":"Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, et al. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. J Clin Oncol. 2015;33(28):3124\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.59.7401.","journal-title":"J Clin Oncol"},{"issue":"1","key":"600_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1158\/1055-9965.EPI-15-0455","volume":"25","author":"C Hu","year":"2016","unstructured":"Hu C, Hart SN, Bamlet WR, Moore RM, Nandakumar K, Eckloff BW, et al. Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients. Cancer Epidemiol Biomarkers Prev. 2016;25(1):207\u201311. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-0455.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"23","key":"600_CR21","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","volume":"319","author":"C Hu","year":"2018","unstructured":"Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319(23):2401\u20139. https:\/\/doi.org\/10.1001\/jama.2018.6228.","journal-title":"JAMA"},{"issue":"1","key":"600_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13073-017-0430-4","volume":"9","author":"AL Johns","year":"2017","unstructured":"Johns AL, McKay SH, Humphris JL, Pinese M, Chantrill LA, Mead RS, et al. Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Med. 2017;9(1):41. https:\/\/doi.org\/10.1186\/s13073-017-0430-4.","journal-title":"Genome Med"},{"issue":"5897","key":"600_CR23","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801\u20136. https:\/\/doi.org\/10.1126\/science.1164368.","journal-title":"Science"},{"issue":"4","key":"600_CR24","first-page":"266","volume":"7","author":"AP Klein","year":"2001","unstructured":"Klein AP, Hruban RH, Brune KA, Petersen GM, Goggins M. Familial pancreatic cancer. Cancer J. 2001;7(4):266\u201373.","journal-title":"Cancer J"},{"issue":"1","key":"600_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mc.2085","volume":"51","author":"AP Klein","year":"2012","unstructured":"Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog. 2012;51(1):14\u201324. https:\/\/doi.org\/10.1002\/mc.2085.","journal-title":"Mol Carcinog"},{"issue":"1","key":"600_CR26","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1186\/s40064-016-2847-4","volume":"5","author":"JH Lee","year":"2016","unstructured":"Lee JH, Kim Y, Choi JW, Kim JS. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Springer plus. 2016;5(1):1172. https:\/\/doi.org\/10.1186\/s40064-016-2847-4.","journal-title":"Springer plus"},{"issue":"1","key":"600_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/carcin\/bgz086","volume":"41","author":"Z Li","year":"2020","unstructured":"Li Z, Shao C, Liu X, Lu X, Jia X, Zheng X, et al. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. Carcinogenesis. 2020;41(1):44\u201355. https:\/\/doi.org\/10.1093\/carcin\/bgz086.","journal-title":"Carcinogenesis"},{"key":"600_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bpg.2005.10.001","volume":"20","author":"AB Lowenfels","year":"2006","unstructured":"Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:197\u2013209. https:\/\/doi.org\/10.1016\/j.bpg.2005.10.001.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"40","key":"600_CR29","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1038\/s41388-021-01984-2","volume":"40","author":"L Magrin","year":"2021","unstructured":"Magrin L, Fanale D, Brando C, Fiorino A, Corsini LR, Sciacchitano R, et al. POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes. Oncogene. 2021;40(40):5893\u2013901. https:\/\/doi.org\/10.1038\/s41388-021-01984-2.","journal-title":"Oncogene"},{"issue":"9","key":"600_CR30","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","volume":"318","author":"D Mandelker","year":"2017","unstructured":"Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318(9):825\u201335. https:\/\/doi.org\/10.1001\/jama.2017.11137. Erratum. In: JAMA. 2018;320(22):2381.","journal-title":"JAMA"},{"issue":"6","key":"600_CR31","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4161\/cbt.2.6.530","volume":"2","author":"H Matsubayashi","year":"2003","unstructured":"Matsubayashi H, Fukushima N, Sato N, Brune K, Canto M, Yeo CJ, et al. Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer. Cancer Biol Ther. 2003;2(6):652\u20135.","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"600_CR32","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1136\/gut.2005.074534","volume":"54","author":"R McWilliams","year":"2005","unstructured":"McWilliams R, Highsmith WE, Rabe KG, de Andrade M, Tordsen LA, Holtegaard LM, et al. Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma. Gut. 2005;54(11):1661\u20132. https:\/\/doi.org\/10.1136\/gut.2005.074534.","journal-title":"Gut"},{"issue":"1","key":"600_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/cncr.24697","volume":"116","author":"RR McWilliams","year":"2010","unstructured":"McWilliams RR, Petersen GM, Rabeb KG, Holtegaard LM, Lynch PJ, Bishop MD, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma. Cancer. 2010;116(1):203\u20139. https:\/\/doi.org\/10.1002\/cncr.24697.","journal-title":"Cancer"},{"issue":"4","key":"600_CR34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/humu.22956","volume":"37","author":"S Moghadasi","year":"2016","unstructured":"Moghadasi S, Eccles DM, Devilee P, Vreeswijk MP, van Asperen CJ. Classification and clinical management of variants of uncertain significance in high penetrance cancer predisposition genes. Hum Mutat. 2016;37(4):331\u20136. https:\/\/doi.org\/10.1002\/humu.22956.","journal-title":"Hum Mutat"},{"issue":"12","key":"600_CR35","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1038\/s41436-020-0922-2","volume":"22","author":"P Mur","year":"2020","unstructured":"Mur P, Garc\u00eda-Mulero S, Del Valle J, Magraner-Pardo L, Vidal A, Pineda M, et al. Role of POLE and POLD1 in familial cancer. Genet Med. 2020;22(12):2089\u2013100. https:\/\/doi.org\/10.1038\/s41436-020-0922-2.","journal-title":"Genet Med"},{"issue":"11","key":"600_CR36","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/humu.20880","volume":"29","author":"SE Plon","year":"2008","unstructured":"Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29(11):1282\u201391. https:\/\/doi.org\/10.1002\/humu.20880.","journal-title":"Hum Mutat"},{"issue":"5","key":"600_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"issue":"12","key":"600_CR38","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1007\/s11605-011-1639-y","volume":"15","author":"DW Rittenhouse","year":"2011","unstructured":"Rittenhouse DW, Talbott VA, Anklesaria Z, Brody JR, Witkiewicz AK, Yeo CJ. Subject review: pancreatic ductal adenocarcinoma in the setting of mutations in the cystic fibrosis transmembrane conductance regulator gene: case report and review of the literature. J Gastrointest Surg. 2011;15(12):2284\u201390. https:\/\/doi.org\/10.1007\/s11605-011-1639-y.","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"600_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.CD-11-0194","volume":"2","author":"NJ Roberts","year":"2012","unstructured":"Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2(1):41\u20136. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0194.","journal-title":"Cancer Discov"},{"issue":"2","key":"600_CR40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1158\/2159-8290.CD-15-0402","volume":"6","author":"NJ Roberts","year":"2016","unstructured":"Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S, et al. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 2016;6(2):166\u201375. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0402.","journal-title":"Cancer Discov"},{"issue":"6","key":"600_CR41","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/jso.25376","volume":"119","author":"AM Roch","year":"2019","unstructured":"Roch AM, Schneider J, Carr RA, Lancaster WP, House MG, Zyromski NJ, et al. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma? J Surg Oncol. 2019;119(6):777\u201383. https:\/\/doi.org\/10.1002\/jso.25376.","journal-title":"J Surg Oncol"},{"issue":"30","key":"600_CR42","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","volume":"35","author":"K Shindo","year":"2017","unstructured":"Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35(30):3382\u201390. https:\/\/doi.org\/10.1200\/JCO.2017.72.3502.","journal-title":"J Clin Oncol"},{"issue":"6","key":"600_CR43","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/PPO.0b013e318278c4a6","volume":"18","author":"S Solomon","year":"2012","unstructured":"Solomon S, Das S, Brand R, Whitcomb DC. Inherited pancreatic cancer syndromes. Cancer J. 2012;18(6):485\u201391. https:\/\/doi.org\/10.1097\/PPO.0b013e318278c4a6.","journal-title":"Cancer J"},{"issue":"2","key":"600_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1200\/JCO.18.01489","volume":"37","author":"EM Stoffel","year":"2019","unstructured":"Stoffel EM, McKernin SE, Brand R, Canto M, Goggins M, Moravek C, et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. J Clin Oncol. 2019;37(2):153\u201364. https:\/\/doi.org\/10.1200\/JCO.18.01489.","journal-title":"J Clin Oncol"},{"issue":"3","key":"600_CR45","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/MPA.0000000000000052","volume":"43","author":"A Sud","year":"2014","unstructured":"Sud A, Wham D, Catalano M, Guda NM. Promising outcomes of screening for pancreatic cancer by genetic testing and endoscopic ultrasound. Pancreas. 2014;43(3):458\u201361. https:\/\/doi.org\/10.1097\/MPA.0000000000000052.","journal-title":"Pancreas"},{"issue":"8","key":"600_CR46","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","volume":"15","author":"MA Tempero","year":"2017","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic adenocarcinoma, Version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(8):1028\u201361. https:\/\/doi.org\/10.6004\/jnccn.2017.0131.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"600_CR47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1200\/jco.2012.30.4_suppl.217","volume":"30","author":"B Tran","year":"2012","unstructured":"Tran B, Moore S, Zogopoulos G, Borgida A, Holter S, Gallinger S, Malcolm JM. Platinum-based chemotherapy (Pt-chemo) in pancreatic adenocarcinoma (PC) associated with BRCA mutations: a translational case series. J Clin Oncol. 2012;30(4):217\u2013217. https:\/\/doi.org\/10.1200\/jco.2012.30.4_suppl.217.","journal-title":"J Clin Oncol"},{"issue":"9","key":"600_CR48","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3390\/jcm8091427","volume":"8","author":"HJ Tsai","year":"2019","unstructured":"Tsai HJ, Chang JS. Environmental risk factors of pancreatic cancer. J Clin Med. 2019;8(9):1427. https:\/\/doi.org\/10.3390\/jcm8091427.","journal-title":"J Clin Med"},{"key":"600_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/acr-20-83","volume":"5","author":"A Vittal","year":"2021","unstructured":"Vittal A, Saha D, Samanta I, Kasi A. CHEK2 mutation in a patient with pancreatic adenocarcinoma-a rare case report. AME Case Rep. 2021;5:5. https:\/\/doi.org\/10.21037\/acr-20-83.","journal-title":"AME Case Rep"},{"key":"600_CR50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fphys.2014.00070","volume":"5","author":"FU Weiss","year":"2014","unstructured":"Weiss FU. Pancreatic cancer risk in hereditary pancreatitis. Front Physiol. 2014;5:70. https:\/\/doi.org\/10.3389\/fphys.2014.00070.","journal-title":"Front Physiol"},{"issue":"8","key":"600_CR51","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1136\/gut.2004.062786","volume":"56","author":"M Wilschanski","year":"2007","unstructured":"Wilschanski M, Durie PR. Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut. 2007;56(8):1153\u201363. https:\/\/doi.org\/10.1136\/gut.2004.062786.","journal-title":"Gut"},{"issue":"7","key":"600_CR52","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1053\/j.gastro.2018.12.039","volume":"156","author":"LD Wood","year":"2019","unstructured":"Wood LD, Yurgelun MB, Goggins MG. Genetics of familial and sporadic pancreatic cancer. Gastroenterology. 2019;156(7):2041\u201355. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.039.","journal-title":"Gastroenterology"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-023-00600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-023-00600-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-023-00600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T10:17:56Z","timestamp":1675073876000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-023-00600-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1186\/s10020-023-00600-1","relation":{},"ISSN":["1528-3658"],"issn-type":[{"type":"electronic","value":"1528-3658"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"11 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Fondazione \u201cCasa Sollievo della Sofferenza\u201d IRCCS Hospital (Prot. No. 96\/CE\/2011). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}